Tvardi Therapeutics reported a net loss of $19.4 million for the nine months ended September 30, 2026, compared to a $10.9 million loss in the prior year period. The company strengthened its liquidity by raising $13.3 million through an at-the-market equity facility, ending the quarter with $22.3 million in cash and cash equivalents.
Tvardi Therapeutics reported third quarter 2026 financial results and provided updates on its STAT3 inhibitor pipeline, including plans to advance TTI-109 into clinical development for ulcerative colitis in 2027. The company also confirmed it expects a topline readout for its Phase 1b/2 study of TTI-101 in hepatocellular carcinoma in early Q1 2027.
Term
Q3 2026
“We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps.”
Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi